Russell Investments Core Plus Bond ETF(BD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BD Russell Investments Core Plus Bond ETF

盘后交易 08-21 17:30:32 EDT

24.74

-0.03

-0.10%

盘后24.74

+0.000.00%

16:04 EDT

最高24.74	最低24.74	成交量39.00
今开24.76	昨收24.76	日振幅0.00%
总市值5,986万	流通市值5,986万	总股本242.00万
成交额965.00	换手率0.00%	流通股本242.00万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BD","market":"US","secType":"STK","nameCN":"Russell Investments Core Plus Bond ETF","latestPrice":24.735,"timestamp":1787342400000,"preClose":24.7606,"halted":0,"volume":39,"hourTrading":{"tag":"盘后","latestPrice":24.735,"preClose":24.735,"latestTime":"16:04 EDT","volume":2,"amount":49.47,"timestamp":1787342650304,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0010339006324564322,"floatShares":2420004,"shares":2420004,"eps":0,"marketStatus":"盘后交易","change":-0.0256,"latestTime":"08-21 17:30:32 EDT","open":24.7606,"high":24.735,"low":24.735,"amount":965,"amplitude":0,"askPrice":30.95,"askSize":200,"bidPrice":18.57,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787356800000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":24.7606,"nav":24.790765,"aum":59993650.48,"dividendRate":0.004881,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.735,"preClose":24.735,"latestTime":"16:04 EDT","volume":2,"amount":49.47,"timestamp":1787342650304,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.799182},"requestUrl":"/m/hq/s/BD/tweets","defaultTab":"tweets","newsList":[{"id":"2660477171","title":"港股异动 | 先声药业(02096)早盘涨超5% 今日将发中期业绩 创新药及BD收入带动业绩高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2660477171","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660477171?lang=zh_cn&edition=full","pubTime":"2026-08-20 10:32","pubTimestamp":1787193141,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，先声药业早盘涨超5%，截至发稿，涨4.27%，报12.69港元，成交额4017.4万港元。消息面上，先声药业将于8月21日召开2026年中期业绩发布会。主要归因于创新药收入和对外授权许可收入的增加。预计公司全年内生业务维持中报预告趋势，同时利润端受益BD继续跨越式提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","IBBQ","KCAI","BK1574","159992","MEDX","BK1583","BK4585","BK1161","06978","BK1191","VXUS","02096","BD","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660448051","title":"【券商聚焦】国盛证券首予石药集团（01093）买入评级 指其创新转型与BD出海双轮驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448051","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660448051?lang=zh_cn&edition=full","pubTime":"2026-08-19 15:44","pubTimestamp":1787125471,"startTime":"0","endTime":"0","summary":"国盛证券指出，公司构建“自研管线+BD出海”双轮驱动创新研发体系。通过可比公司估值法，给予公司2027年23倍PE，对应目标价13.41港元，首次覆盖给予“买入”评级。报告同时提示研发失败、产品商业化不及预期、BD里程碑收入确认节奏不确定、集采政策持续影响、估值与盈利预测假设及专利知识产权等风险。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988694","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093","KCE","002670","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659421174","title":"海外BD大单落定，国产胰岛素龙头借力减重药能否开启新增长曲线？","url":"https://stock-news.laohu8.com/highlight/detail?id=2659421174","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659421174?lang=zh_cn&edition=full","pubTime":"2026-08-16 17:05","pubTimestamp":1786871100,"startTime":"0","endTime":"0","summary":"海归博士创立的胰岛素龙头，净利润难复巅峰在凭借博凡格鲁肽获得市场高度关注之前，甘李药业最为人熟知的身份是国产胰岛素龙头。在国内三代胰岛素市场上，除诺和诺德、赛诺菲、礼来三大外企外，甘李药业市场份额最高，是国产三代胰岛素龙头。拿下海外授权许可大单，甘李药业能否迎来爆发？此次与美纳里尼的授权金额，也创出了博凡格鲁肽授权金额新高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2026-08-16/doc-ininnzcn1015795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659317314","title":"全球客户“反向出差”到中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2659317314","media":"央视财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659317314?lang=zh_cn&edition=full","pubTime":"2026-08-15 22:18","pubTimestamp":1786803480,"startTime":"0","endTime":"0","summary":"在央视财经《对话》节目中，主持人陈伟鸿与几位中国科技企业的创始人聊起了一个有趣的变化：过去，中国企业出海往往意味着带着样品和销售团队满世界飞；而现在，一种相反的场景正在频繁出现——海外客户主动来中国“出差”。数据正在印证这一趋势：5月落幕的杭州第二届国际人形机器人展，累计达成合作签约56项、合作意向237项，总金额超213亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608153842453753.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608153842453753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PBOT","ARTY","VTHR","AGIX","BD","ROBO","AIPO","CHAT","QTOC","KOMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152904","title":"别慌！机构资金都流向了这里！","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152904","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659152904?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:23","pubTimestamp":1786623796,"startTime":"0","endTime":"0","summary":"今天（8月13日），A股早盘三大指数集体高开，CPO等板块全线走强，“易中天”强势上涨，封板个股比比皆是。然而，下午2点左右，画风突变，上午追高的资金，午后被悉数套牢，截至收盘，仅创新药一枝独秀。那么，科技冲高回落，医药逆势爆发，这究竟发生了什么？今天这篇文章，笔者将逐一拆解。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133840675371.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133840675371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","KURE","LU1770034418.SGD","LU0228659784.USD","BK1588","OCS","03130","07233","02827","LU1303224171.USD","83130","BK1161","MEDX","LU2328871848.SGD","LU0588546209.SGD","BD","BK1574","CPI","83188","LU0828237510.HKD","82846","BK4007","02846","06160","LU0307460666.USD","06978","IBBQ","LU1719994722.HKD","BK1583","03188","LU1969619763.USD","399300","BK1147","159982","LU1251922891.USD","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659186026","title":"从“抢BD”到重现金流 创新药产业投资逻辑生变","url":"https://stock-news.laohu8.com/highlight/detail?id=2659186026","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659186026?lang=zh_cn&edition=full","pubTime":"2026-08-13 07:26","pubTimestamp":1786577165,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06978","159399","BK1574","SPHQ","BK4585","MEDX","IBBQ","BK1161","LNGR","BD","BK4588","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659186206","title":"从“抢BD”到重现金流 创新药产业投资逻辑生变","url":"https://stock-news.laohu8.com/highlight/detail?id=2659186206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659186206?lang=zh_cn&edition=full","pubTime":"2026-08-13 07:15","pubTimestamp":1786576513,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","BK4588","LNGR","BK4585","SPHQ","MEDX","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950539","title":"百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950539?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:01","pubTimestamp":1786402877,"startTime":"0","endTime":"0","summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["RVMD","KURE","BBH","BK1500","BK1161","06160","603087","LU1719994722.HKD","BK1588","LU0889565916.HKD","CANC","LU1969619763.USD","LU1770034418.SGD","IE00BJT1NW94.SGD","LU0588546209.SGD","LU1251922891.USD","BK1515","BK4585","BK0239","09939","BK4139","IE0002141913.USD","BK1574","LU0307460666.USD","LU1303224171.USD","BK1583","LU0228659784.USD","IE00BFTCPJ56.SGD","LU0828237510.HKD","BK4588","IE00B2B36J28.USD","IE0009355771.USD","688235","PTH","IE00B4R5TH58.HKD","ONC","IE0009354923.USD","IE00BJJMRZ35.SGD","BD","IDNA","LU2328871848.SGD","LU0109394709.USD","159938","BK4526","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658986658","title":"从BD高光到亏损回归，百利天恒面临什么考题？","url":"https://stock-news.laohu8.com/highlight/detail?id=2658986658","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658986658?lang=zh_cn&edition=full","pubTime":"2026-08-10 15:49","pubTimestamp":1786348144,"startTime":"0","endTime":"0","summary":"相对于坎坷的赴港闯关之路，在生物科技这条赛道上，百利天恒已有产品实现商业化。从项目成熟度看，百利天恒并非停留在“早期研发概念验证”阶段。盈利高峰来自授权兑现，亏损继续扩大百利天恒最容易抓住眼球的，是其利润表在近两年出现过明显波动。这组数据本身已经足够说明，百利天恒并不是一家已经进入稳定盈利通道的创新药企业。从这个角度看，百利天恒的长板与短板都很鲜明。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786328428501757201","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["688506","BD","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658792716","title":"BD交易破千亿美元 中国创新药距离“全球大单品”还有多远？","url":"https://stock-news.laohu8.com/highlight/detail?id=2658792716","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658792716?lang=zh_cn&edition=full","pubTime":"2026-08-09 12:36","pubTimestamp":1786250165,"startTime":"0","endTime":"0","summary":"8月5日，上海。2026沙利文峰会生命科学新投资高峰论坛上，一组数据让在场者屏息：2026年上半年，中国创新药对外授权（License-out）交易潜在总额达1100亿美元，交易规模达到2025年全年的八成。全球Top10BD交易中，中国独占8席。八年前，当港交所18A章刚刚落地时，中国创新药企还在用“烧十年钱、做研发、等审批”的循环艰难求生。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608093835903315.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608093835903315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KURE","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656374770","title":"“新新三样”之中国创新药：千亿级BD背后的体系突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2656374770","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656374770?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:33","pubTimestamp":1785763991,"startTime":"0","endTime":"0","summary":"今年以来，中国制造出海出现了越来越多新面孔。前两年，电动载人汽车、锂电池、太阳能电池被称为出口“新三样”，而今年上半年，机器人、人工智能、创新药成为未来产业方向的“新新三样”。数据显示，中国创新药企2026年上半年的海外授权（BD）交易总额，逼近2025年全年1357亿美元的七成，较2024年更是近乎翻倍。然而，比这一惊人数字更值得关注的，是交易结构的深层质变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033830056118.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033830056118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656322031","title":"【券商聚焦】华泰证券维持先声药业（02096）买入评级 指新品放量及BD常态化","url":"https://stock-news.laohu8.com/highlight/detail?id=2656322031","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656322031?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:18","pubTimestamp":1785748719,"startTime":"0","endTime":"0","summary":"在行业波动背景下，公司超预期的业绩表现展现了新品种的强烈市场需求及高管变动后的效率提升，同时BD的常态化有望带来持续新增量。预计全年内生业务维持中报预告趋势，利润端受益于BD将继续跨越式提升。此外，在SIM0709年初实现BD及SIM0500后续潜在里程碑等带动下，预计公司合作收入将步入常态化，带来持续的收入增量。TCE平台SIM0500的I期数据有望年内读出，TOPOi毒素ADC平台已通过SIM0613和SIM0505的BD出海得到全面验证。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987337","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","BD","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655335512","title":"第十二批国采现场：多家金融机构到场介绍“集采贷”“BD贷”等服务产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2655335512","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655335512?lang=zh_cn&edition=full","pubTime":"2026-07-31 10:46","pubTimestamp":1785465967,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BD","FISI","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653758618","title":"专访百奥赛图沈月雷：“揭秘”一笔四个月就达成的BD合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2653758618","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653758618?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:15","pubTimestamp":1784708100,"startTime":"0","endTime":"0","summary":"　　从双方正式启动合作到完成协议签署，历时仅仅约四个月，回顾百奥赛图与纳斯达克上市公司Whitehawk Therapeutics的BD合作，整个项目推进速度远快于行业同类项目。百奥赛图董事长兼CEO沈月雷博士在接受动脉网访谈时如此评价。　　据了解，近日百奥赛图与Whitehawk Therapeutics， Inc．宣布双方已签署一项全球战略合作协议，涵盖多个双特异性抗体偶联药物研发项目，双方将共同推进多元化的新一代治疗产品管线。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/enterprise/cn/2026-07-22/doc-iniisiee8049992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD","688796","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653237792","title":"辽BD*****、辽BF*****、辽BT****、辽B*****，你被曝光了！大连为啥这么做？","url":"https://stock-news.laohu8.com/highlight/detail?id=2653237792","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653237792?lang=zh_cn&edition=full","pubTime":"2026-07-21 11:44","pubTimestamp":1784605440,"startTime":"0","endTime":"0","summary":"辽望观天下）最近，大连对出租车行业刚柔并济的管理，收获“大赞”。大连同步推出“的哥的姐说大连，城市故事传四方”活动，鼓励司机为外来乘客讲城市历史、风土人情。不回避服务乱象、主动滋养行业荣誉感，内外兼修，才能让城市口碑行稳致远。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-07-21/doc-iniiptrh9371401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651879434","title":"半年BD狂飙千亿、龙头预增13倍！创新药涨停潮再起","url":"https://stock-news.laohu8.com/highlight/detail?id=2651879434","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651879434?lang=zh_cn&edition=full","pubTime":"2026-07-15 13:50","pubTimestamp":1784094601,"startTime":"0","endTime":"0","summary":"政策密集加码","market":"hk","thumbnail":"https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5584162","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1574","BK0028","600664","BK1161","BK0060","BK0216","BK0012","688192","159992","IBBQ","000566","BK0239","BK0070","MEDX","300149","BK0146","06978","BD","002940","BK0188","BK0077","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651482441","title":"“BD红利”进入兑现窗口 创新药企价值加速分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2651482441","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651482441?lang=zh_cn&edition=full","pubTime":"2026-07-15 07:28","pubTimestamp":1784071736,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","BD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651481540","title":"“BD红利”进入兑现窗口 创新药企价值加速分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2651481540","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651481540?lang=zh_cn&edition=full","pubTime":"2026-07-15 04:37","pubTimestamp":1784061458,"startTime":"0","endTime":"0","summary":"持续升温的创新药海外授权交易（以下简称“创新药BD”）正进入价值兑现窗口。近日，石药集团（01093.HK）发布公告称，公司于7月10日收到阿斯利康支付的2500万美元研发里程碑付款。此前，公司已于5月29日收到该BD协议项下首付款12亿美元。对此，业内人士表示，2026年以来，中国创新药BD交易开始从“规模出海”迈向“价值出海”，进入常态化、高质量增长的新周期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607153806272733.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153806272733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","MEDX","06978","159992","IBBQ","BD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651568164","title":"【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651568164?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","01177","LU1961090484.USD","LU0516422366.SGD","02269","BK1588","LU2097828631.EUR","LU0455707207.USD","LU0348825331.USD","09995","LU0348735423.USD","01801","02142","LU0051755006.USD","LU1993786604.SGD","09926","IE00B5MMRT66.SGD","LU1960683339.HKD","LU2097828474.EUR","01877","LU0067412154.USD","BK1161","BK1515","09688","LU0501845795.SGD","IE0008369823.USD","MEDX","LU0359202008.SGD","LU1226288170.HKD","BD","LU0348784397.USD","LU0456846285.SGD","LU1688375341.USD","02616","06160","LU2488822045.USD","06978","IBBQ","06185","LU1969619763.USD","LU2242644610.SGD","IE00B0JY6N72.USD","LU1807302812.USD","LU1813983027.USD","01093","159992","IE0008368742.USD","601066","KCE","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907376","title":"【券商聚焦】华源证券维持康诺亚-B(02162)买入评级 指商业化与BD共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907376","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650907376?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:39","pubTimestamp":1783665555,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华源证券发布研报指，康诺亚-B 正迈入商业化放量与BD收益兑现的共振阶段，2026年下半年多项关键催化剂值得期待。首先，CMG901若于2026年下半年向美国FDA申报并于2027年进入商业化，公司将在收到6300万美元首付款的基础上，逐步兑现总额超11亿美元的潜在里程碑及销售分成，持续增厚业绩。华源证券预计公司2026-2028年归母净利润分别为11.67/0.59/5.50亿元。考虑到公司商业化放量可期，伴随着商业化进程持续推进，BD收益有望逐步兑现，维持“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985582","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","BD","KCE","02162"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0026},{"period":"1month","weight":-0.0058},{"period":"3month","weight":-0.0127},{"period":"ytd","weight":-0.0127}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.0227},{"period":"6month","weight":0.1061},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"ARCA","name":"Russell Investments Core Plus Bond ETF","nameEN":"Russell Investments Core Plus Bond ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Russell Investments Core Plus Bond ETF(BD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Russell Investments Core Plus Bond ETF(BD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Russell Investments Core Plus Bond ETF,BD,Russell Investments Core Plus Bond ETF股票,Russell Investments Core Plus Bond ETF股票老虎,Russell Investments Core Plus Bond ETF股票老虎国际,Russell Investments Core Plus Bond ETF行情,Russell Investments Core Plus Bond ETF股票行情,Russell Investments Core Plus Bond ETF股价,Russell Investments Core Plus Bond ETF股市,Russell Investments Core Plus Bond ETF股票价格,Russell Investments Core Plus Bond ETF股票交易,Russell Investments Core Plus Bond ETF股票购买,Russell Investments Core Plus Bond ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Russell Investments Core Plus Bond ETF(BD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Russell Investments Core Plus Bond ETF(BD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}